Neal Warshoff, D.O. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13005 Southern Blvd, Suite 235, Loxahatchee, FL 33470 Phone: 561-795-1022 Fax: 561-792-0361 |
News Archive
Researchers from Boston University School of Medicine (BUSM) have found that when attempting to pass tanning bed legislation, successful advocates collaborate with local and national organizations and lobbyists and have direct contact with the sponsoring legislator to aid in the passage of the bill. These findings, which appear on-line in the Journal of the American Academy of Dermatology, also identify strong lobbying efforts by the tanning bed industry as the biggest barrier to passing tanning bed legislation.
Cardiac allograft vasculopathy (CAV), also known as chronicle rejection, is a leading cause of graft (foreign heart) loss and death in patients who survive the first year after heart transplantation. The typical pathological change of CAV is gradually thickening of coronary wall in "foreign" heart due to continuous immunological reaction between donated heart and the host. In some cases, undetected CAV may silently cause graft failure with global myocardial ischemia without any documented infarction signs. Thus, continually monitoring development of asymptomatic CAV is important for selecting prophylactic strategies to get better prognosis. However, most current examinations of detecting CAV are invasive and with certain risks.
Anyone familiar with the devastating statistics knows that inexperience plus a driver's license can be a dangerous combination. For teen drivers, lives can be forever changed in an instant.
Women remain underrepresented in cardiovascular clinical trials despite guidelines and legal requirements developed almost 30 years ago to ensure broader inclusivity, according to a report from the American College of Cardiology Cardiovascular Disease in Women Committee published today in the Journal of the American College of Cardiology.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.
› Verified 5 days ago